Cole Wayant1, Greg Aran2, Bradley S Johnson2, Matt Vassar2. 1. Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences , Tulsa, OK, USA. cole.wayant@okstate.edu. 2. Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences , Tulsa, OK, USA.
Abstract
IMPORTANCE: Selective outcome reporting bias in oncology drug advertisements may encourage misconceptions about a drug's efficacy profile. OBJECTIVE: We sought to determine the rates of selective outcome reporting in published cancer clinical trials and in television and print advertisements for anticancer medications. We also quantified the number of advertisements that did not include or cite any studies with mature overall survival (OS) data (i.e., data with all required patient events for final analysis). DESIGN/SETTING/PARTICIPANTS: We conducted a cross-sectional investigation of advertisements uploaded to the AdPharm Database (repository of pharmaceutical advertisements); the clinical trials supporting the ads; and the trial registrations associated with the trials. Data were extracted by two investigators who were blinded to each other's data. MAIN OUTCOME MEASURES: The first co-primary objective was to investigate selective outcome reporting between trial registrations and published trials. The second co-primary objective was to investigate selective outcome reporting between the same published trials and drug advertisements. RESULTS: We included 74 advertisements and 48 clinical trials. Print ads were the most common (n = 66), and most print advertisements were targeted to health care providers (n = 55, 83.3%). Overall, 41/48 (85.4%) trials were registered prior to study enrollment, and 41/48 (85.4%) did not deviate from the registered primary endpoints. Across all advertisements (n = 74), statistically significant endpoints were more often reported (unadjusted risk ratio [uRR] 1.26; 95% confidence interval [CI] (1.14-1.40)) and 22/55 (40.0%) advertisements cited trials with immature overall survival data (i.e., data without the required number of events for final analysis). CONCLUSIONS: In our sample, statistically significant endpoints were more commonly reported than nonsignificant endpoints. Immature endpoints (those analyzed before the required number of accrued patient events) were often reported. By reporting only significant endpoints and those that are immature, advertisers may encourage misconceptions about a drug's efficacy profile.
IMPORTANCE: Selective outcome reporting bias in oncology drug advertisements may encourage misconceptions about a drug's efficacy profile. OBJECTIVE: We sought to determine the rates of selective outcome reporting in published cancer clinical trials and in television and print advertisements for anticancer medications. We also quantified the number of advertisements that did not include or cite any studies with mature overall survival (OS) data (i.e., data with all required patient events for final analysis). DESIGN/SETTING/PARTICIPANTS: We conducted a cross-sectional investigation of advertisements uploaded to the AdPharm Database (repository of pharmaceutical advertisements); the clinical trials supporting the ads; and the trial registrations associated with the trials. Data were extracted by two investigators who were blinded to each other's data. MAIN OUTCOME MEASURES: The first co-primary objective was to investigate selective outcome reporting between trial registrations and published trials. The second co-primary objective was to investigate selective outcome reporting between the same published trials and drug advertisements. RESULTS: We included 74 advertisements and 48 clinical trials. Print ads were the most common (n = 66), and most print advertisements were targeted to health care providers (n = 55, 83.3%). Overall, 41/48 (85.4%) trials were registered prior to study enrollment, and 41/48 (85.4%) did not deviate from the registered primary endpoints. Across all advertisements (n = 74), statistically significant endpoints were more often reported (unadjusted risk ratio [uRR] 1.26; 95% confidence interval [CI] (1.14-1.40)) and 22/55 (40.0%) advertisements cited trials with immature overall survival data (i.e., data without the required number of events for final analysis). CONCLUSIONS: In our sample, statistically significant endpoints were more commonly reported than nonsignificant endpoints. Immature endpoints (those analyzed before the required number of accrued patient events) were often reported. By reporting only significant endpoints and those that are immature, advertisers may encourage misconceptions about a drug's efficacy profile.
Authors: Dirk Bassler; Matthias Briel; Victor M Montori; Melanie Lane; Paul Glasziou; Qi Zhou; Diane Heels-Ansdell; Stephen D Walter; Gordon H Guyatt; David N Flynn; Mohamed B Elamin; Mohammad Hassan Murad; Nisrin O Abu Elnour; Julianna F Lampropulos; Amit Sood; Rebecca J Mullan; Patricia J Erwin; Clare R Bankhead; Rafael Perera; Carolina Ruiz Culebro; John J You; Sohail M Mulla; Jagdeep Kaur; Kara A Nerenberg; Holger Schünemann; Deborah J Cook; Kristina Lutz; Christine M Ribic; Noah Vale; German Malaga; Elie A Akl; Ignacio Ferreira-Gonzalez; Pablo Alonso-Coello; Gerard Urrutia; Regina Kunz; Heiner C Bucher; Alain J Nordmann; Heike Raatz; Suzana Alves da Silva; Fabio Tuche; Brigitte Strahm; Benjamin Djulbegovic; Neill K J Adhikari; Edward J Mills; Femida Gwadry-Sridhar; Haresh Kirpalani; Heloisa P Soares; Paul J Karanicolas; Karen E A Burns; Per Olav Vandvik; Fernando Coto-Yglesias; Pedro Paulo M Chrispim; Tim Ramsay Journal: JAMA Date: 2010-03-24 Impact factor: 56.272
Authors: Dominick L Frosch; Patrick M Krueger; Robert C Hornik; Peter F Cronholm; Frances K Barg Journal: Ann Fam Med Date: 2007 Jan-Feb Impact factor: 5.166
Authors: Angela B Mariotto; K Robin Yabroff; Yongwu Shao; Eric J Feuer; Martin L Brown Journal: J Natl Cancer Inst Date: 2011-01-12 Impact factor: 13.506
Authors: Andrew Ross; David George; Cole Wayant; Tom Hamilton; Matt Vassar Journal: JAMA Otolaryngol Head Neck Surg Date: 2019-05-01 Impact factor: 6.223